Mary Reumuth
Director Financiero/CFO en KALA BIO, INC. .
Fortuna: 462 797 $ al 30/04/2024
Cargos activos de Mary Reumuth
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
KALA BIO, INC. | Comptroller/Controller/Auditor | 01/02/2014 | - |
Director Financiero/CFO | 01/02/2014 | - | |
Treasurer | 01/02/2014 | 01/07/2017 | |
OLINK HOLDING AB | Director/Miembro de la Junta | 07/04/2022 | - |
Independent Dir/Board Member | 07/04/2022 | - |
Historial de carrera de Mary Reumuth
Antiguos cargos conocidos de Mary Reumuth.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 01/05/2011 | 01/06/2012 |
VERENIUM CORP | Director Financiero/CFO | 01/12/2007 | 01/03/2011 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Formación de Mary Reumuth.
Texas A&M University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Canadá | 2 |
Turquía | 2 |
Operativa
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 2 |
Sectorial
Health Technology | 6 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
KALA BIO, INC. | Health Technology |
OLINK HOLDING AB | Health Technology |
Empresas privadas | 4 |
---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Verenium Corp.
Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Mary Reumuth
- Experiencia